DrugBiological
Odronextamab clinical trials
Also written REGN1979, WHO 11035 and Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody REGN1979.
- studies test it
- 15
- open now
- 11
- in phase 3
- 5
- first study started
- 2015
Keep track of what changes. Save the odronextamab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Studies by the year they started
15 studies that test it; most in 2025 (5)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 1 |
| 2023 | 4 |
| 2024 | 2 |
| 2025 | 5 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 6
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 5
Regeneron Pharmaceuticals (10) · City of Hope Medical Center (1) · University of Washington (1) · University of California, Davis (1) · Gottfried von Keudell, MD PhD (1) · University of Birmingham (1)
Often tested with
Tested in the same studies.
Chimeric Antigen Receptor T-cells (3) · Rituximab (2) · Chimeric Antigen Receptor T-Cell Therapy|Chimeric Antigen Receptor T-cell Therapy (2) · Cemiplimab (1) · REGN9220 (1) · Zanubrutinib (1) · Vonsetamig (1) · Anti-CD22/Anti-CD28 Bispecific Antibody REGN5837 (1)
Studies
Open first, then newest update. How each study uses odronextamab is read from its arms, and is right about nine times in ten.
Testing it · 15
- REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)Not yet recruitingPhase 1/2Regeneron PharmaceuticalsNCT07887750Written as Odronextamab
- A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell LymphomaRecruitingPhase 3Regeneron PharmaceuticalsNCT06091865Written as Odronextamab
- A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone LymphomaRecruitingPhase 3Regeneron PharmaceuticalsNCT06149286Written as Odronextamab
- A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaRecruitingPhase 3Regeneron PharmaceuticalsNCT06091254Written as Odronextamab
- Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's TransformationRecruitingPhase 1City of Hope Medical CenterNCT06735664Written as Odronextamab
- Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus NephritisRecruitingPhase 1Regeneron PharmaceuticalsNCT06975787Written as Odronextamab
- Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-TRecruitingPhase 2University of WashingtonNCT06784726Written as Odronextamab
- Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell TherapyRecruitingPhase 2University of California, DavisNCT06854159Written as Odronextamab
- A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin LymphomasRecruitingPhase 1Regeneron PharmaceuticalsNCT05685173Written as Odronextamab
- Odronextamab in Low Tumor Volume Advanced FLRecruitingPhase 2Gottfried von Keudell, MD PhDNCT07128641Written as Odronextamab
- A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin LymphomaRecruitingPhase 2/3University of BirminghamNCT05991388Written as Odronextamab
- A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer TherapiesActive, not recruitingPhase 2Regeneron PharmaceuticalsNCT03888105Written as Odronextamab
- A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell MalignanciesCompletedPhase 1Regeneron PharmaceuticalsNCT02651662Written as odronextamab
- A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin LymphomaActive, not recruitingPhase 3Regeneron PharmaceuticalsNCT06230224Written as Odronextamab
- Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell MalignanciesCompletedPhase 1Regeneron PharmaceuticalsNCT02290951Written as Odronextamab multiple dose levels
Given in every arm · 1 — odronextamab is usual care beside what is tested
Codes
What other systems call odronextamab · ClinicalTrials.gg INT015708
- UNII (FDA) 8R5CM46UIOODRONEXTAMABOne source FDA
- NCI Thesaurus C119615OdronextamabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 8R5CM46UIO | ODRONEXTAMAB | One source FDA |
| NCI Thesaurus | C119615 | Odronextamab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.